Plain-English translation of NCT06602622 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether switching to a medication called doravirine (combined with two other HIV drugs) helps people with HIV lose weight better than staying on their current regimen. People living with HIV who are taking medications sometimes experience unintended weight gain, and this study wants to see if this newer medication option might help address that side effect.
Many people taking current HIV medications experience unwanted weight gain as a side effect, which can lead to other health problems. Researchers want to know if this medication might be a better option for people whose HIV is well-controlled but who are struggling with weight gain.
You will be randomly assigned to either keep taking your current HIV medication or switch to doravirine with two other HIV drugs (one pill daily). Over 48 weeks, you will have regular clinic visits where researchers will measure your weight, body measurements, and blood work to track changes. You'll also answer questions about your diet, exercise, and any other medications you're taking—but you should not make major changes to your exercise routine or start a structured weight loss program during the study.
AI-generated summary from trial data · Aug 7, 2026 · Not medical advice
Mexico